Oncology

Articles:
158 Palbociclib and Letrozole in Advanced Breast Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1607303

157 A personalized DC/AML fusion cell vaccine promotes the expansion of leukemia-specific T cells and prolonged remission in patients.
http://stm.sciencemag.org/content/8/368/368ra171.abstract

156 Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
http://www.nejm.org/doi/full/10.1056/NEJMoa1609214

155 Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1609709

154 Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
http://www.nejm.org/doi/full/10.1056/NEJMoa1611299

153 Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
http://www.nejm.org/doi/full/10.1056/NEJMoa1602252

152 Mutational signatures associated with tobacco smoking in human cancer.
http://science.sciencemag.org/content/354/6312/618

151 Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1607751

150 Anti-VEGF therapy enhances mechanical barriers to therapy in colorectal cancer liver metastases by increasing hyaluronan deposition.
http://stm.sciencemag.org/content/8/360/360ra135

149 Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
http://www.nejm.org/doi/full/10.1056/NEJMoa1509277

148 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1602253

147 Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1606038

146 Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31388-5/fulltext

145 Cord-Blood Transplantation in Patients with Minimal Residual Disease.
http://www.nejm.org/doi/full/10.1056/NEJMoa1602074?query=featured_home

144 Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
http://www.nejm.org/doi/full/10.1056/NEJMoa1515725

143 Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
http://www.nejm.org/doi/full/10.1056/NEJMoa1604700

142 Economic downturns, universal health coverage, and cancer mortality in high-income and middle-income countries, 1990–2010: a longitudinal analysis.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00577-8/abstract

141 Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30583-9/abstract

140 Genomic Classification and Prognosis in Acute Myeloid Leukemia.
http://www.nejm.org/doi/full/10.1056/NEJMoa1516192

139 Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30587-6/abstract

138 Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger).
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00739-X/abstract

137 PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1603702

136 Clinical trial of blood-brain barrier disruption by pulsed ultrasound.
http://stm.sciencemag.org/content/8/343/343re2

135 Toca 511 and Toca FC show promising results in treating recurrent high-grade glioma, and a specific molecular signature correlates with treatment-related survival.
http://stm.sciencemag.org/content/8/341/341ra75.abstract

134 Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00561-4/abstract

133 Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01317-3/abstract

132 Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1516282

131 Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice.
http://www.pnas.org/content/113/9/E1306.abstract

130 CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1506597

129 Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
http://www.nejm.org/doi/full/10.1056/NEJMoa1513257

128 Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
http://www.nejm.org/doi/full/10.1056/NEJMoa1509388

127 Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01120-4/abstract

126 Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01238-6/abstract

125 Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01037-5/abstract

124 Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01281-7/abstract

123 Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00817-X/abstract

122 Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.
http://www.nejm.org/doi/full/10.1056/NEJMoa1506002

121 Substantial contribution of extrinsic risk factors to cancer development.
http://www.nature.com/nature/journal/v529/n7584/full/nature16166.html

120 Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00986-1/abstract

119 Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00667-4/abstract

Free Images for Presentation: sunipix SUNIPIX